查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1524233

蝨子治疗市场- 按产品类型（非处方药[氯菊酯、除虫菊酯]、处方[伊维菌素、多杀菌素、马拉硫磷]）、类型（品牌、仿製药）、给药途径、状况、剂型、配销通路- 全球预测（2024 年 - 2032 年） ）

Lice Treatment Market - By Product Type (OTC [Permethrin, Pyrethrin], Prescription [Ivermectin, Spinosad, Malathion]), Type (Branded, Generic), Route of Administration, Condition, Dosage Form, Distribution Channel - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于医疗费用增加和可支配收入增加，2024年至2032年全球蝨子治疗市场复合年增长率将超过6.5%。美国经济分析局报告称，截至 2023 年最后一个季度的 12 个月里，美国经济可支配收入成长了 4.2% 这一年里，人均收入从 2022 年底的 57,386 美元增至 2022 年底的 61,084 美元。 2023 年。

随着医疗保健支出的增加，消费者更愿意投资管理蝨子感染的有效解决方案。这种趋势在医疗保健服务和可支配收入水准有所改善的地区尤其明显，从而促进了对传统和创新治疗替代方案的需求。

意识的提高和不断变化的监管环境推动了市场扩张，确保治疗方法符合严格的标准，同时满足不同消费者的喜好。这些因素共同促进了全球蝨子治疗产业的持续成长。

整个蝨子治疗市场根据产品类型、类型、给药途径、状况、剂型、配销通路和地区进行分类。

处方药细分市场在 2024 年至 2032 年间将实现令人印象深刻的复合年增长率。此外，医疗保健专业人员越来越多地开出这些药物，强调它们在管理严重感染或非处方药已被证明不足的情况下的作用。此外，处方治疗被认为更可靠，受到寻求更快、更全面的蝨子感染解决方案的个人的青睐，从而增加了这个专业市场的需求。

到 2032 年，品牌产业将占据相当大的蝨子治疗市场。品牌治疗通常在功效和安全性方面享有盛誉，这可以增强消费者的信心。他们在药局和线上平台上的行销努力和知名度也有助于提高消费者的意识和偏好。此外，品牌治疗经常提供额外的好处。例如用户友好的配方或吸引特定消费者需求的附加功能，进一步推动了它们的受欢迎程度。随着消费者优先考虑有效管理蝨子侵扰的可靠解决方案和便利选择，品牌区隔市场不断扩大。

在预测期内，欧洲蝨子治疗市场将呈现强劲的复合年增长率。移民和旅行的增加导致了蝨子感染的传播，从而引发了对有效治疗的更高需求。此外，学校和工作场所严格的卫生标准需要快速可靠的解决方案，从而推动市场成长。此外，欧洲国家不断增长的医疗保健支出使人们能够更多地获得各种治疗选择，包括处方药和非处方药。这些因素，加上人们对个人卫生和健康意识的不断增强，推动了欧洲蝨子治疗产业的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 蝨子感染盛行率上升
      • 轻鬆获得蝨子治疗产品
      • 偏好天然无毒产品
    • 产业陷阱与挑战
      • 缺乏意识
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

  • 主要趋势
  • 非处方药产品
    • 氯菊酯
    • 除虫菊酯
    • 其他非处方药产品
  • 处方药
    • 伊维菌素
    • 多杀菌素
    • 马拉硫磷
    • 其他处方药

第 6 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 品牌化
  • 通用的

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 口服
  • 专题

第 8 章：市场估计与预测：按条件划分，2021 - 2032 年

  • 主要趋势
  • 头蝨病
  • 体蝨病
  • 阴蝨病

第 9 章：市场估计与预测：按剂型，2021 - 2032

  • 主要趋势
  • 平板电脑
  • 洗髮精
  • 乳液
  • 奶油
  • 其他剂型

第 10 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 其他分销管道

第 11 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 12 章：公司简介

  • Alliance Pharma PLC
  • Azurity Pharmaceuticals, Inc.
  • Fleming Medical Ltd.
  • Oystershell Consumer Health
  • Parapro Pharmaceuticals
  • Perrigo Company plc
  • Prestige Consumer Healthcare Inc.
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Thornton & Ross Ltd.
简介目录
Product Code: 9176

Global Lice Treatment Market will record over 6.5% CAGR from 2024 to 2032, ushered by increased healthcare expenses and rising disposable incomes. The Bureau of Economic Analysis reported a 4.2% growth in disposable income in the U.S. economy for the 12 months ending in the last quarter of 2023. Over the year, per capital income rose from 57,386 at the end of 2022 to 61,084 at the end of 2023.

As healthcare spending amplifies, consumers are more willing to invest in effective solutions for managing lice infestations. This trend is particularly pronounced in regions where access to healthcare services and disposable income levels have improved, fostering demand for traditional as well as innovative treatment alternatives.

Heightened awareness and evolving regulatory landscapes propel the market expansion, ensuring that treatments meet strict standards while catering to diverse consumer preferences. These factors collectively contribute to the sustained growth of the lice treatment industry globally.

The overall lice treatment market is classified based on product type, type, route of administration, condition, dosage form, distribution channel, and region.

The prescription medications segment will register an impressive CAGR between 2024 and 2032. Prescription medications often offer stronger formulations that can effectively eradicate resistant lice strains, addressing growing concerns over treatment efficacy. Additionally, healthcare professionals increasingly prescribe these medications, emphasizing their role in managing severe infestations or cases where over-the-counter remedies have proven inadequate. Moreover, prescription treatments are perceived as more reliable and are preferred by individuals seeking quicker and more comprehensive solutions to lice infestations, boosting demand within this specialized segment of the market.

By 2032, the branded sector will hold a substantial lice treatment market share. Branded treatments often carry established reputations for efficacy and safety, which instill consumer confidence. Their marketing efforts and visibility in pharmacies and online platforms also contribute to increased consumer awareness and preference. Furthermore, branded treatments frequently offer additional benefits. such as user-friendly formulations or added features that appeal to specific consumer needs, further driving their popularity. The branded segment continues to expand as consumers prioritize trusted solutions and convenient options for managing lice infestations effectively.

During the forecast period, the Europe lice treatment market will showcase a robust CAGR. Increased migration and travel contribute to the spread of lice infestations, prompting higher demand for effective treatments. Moreover, stringent hygiene standards in schools and workplaces necessitate quick and reliable solutions, catapulting the market growth. Additionally, rising healthcare expenditures across European countries enable greater access to a variety of treatment options, including both prescription and over-the-counter remedies. These factors, coupled with a growing awareness of personal hygiene and health, propel the expansion of the lice treatment industry in Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of lice infestations
      • 3.2.1.2 Easy availability of lice treatment products
      • 3.2.1.3 Preference for natural and non-toxic products
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of awareness
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 OTC products
    • 5.2.1 Permethrin
    • 5.2.2 Pyrethrin
    • 5.2.3 Other OTC products
  • 5.3 Prescription medications
    • 5.3.1 Ivermectin
    • 5.3.2 Spinosad
    • 5.3.3 Malathion
    • 5.3.4 Other prescription medications

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Branded
  • 6.3 Generic

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Topical

Chapter 8 Market Estimates and Forecast, By Condition, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Pediculosis capitis
  • 8.3 Pediculosis corporis
  • 8.4 Pediculosis pubis

Chapter 9 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)

  • 9.1 Key trends
  • 9.2 Tablets
  • 9.3 Shampoos
  • 9.4 Lotions
  • 9.5 Cream
  • 9.6 Other dosage forms

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

  • 10.1 Key trends
  • 10.2 Hospital pharmacies
  • 10.3 Retail pharmacies
  • 10.4 Other distribution channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 Alliance Pharma PLC
  • 12.2 Azurity Pharmaceuticals, Inc.
  • 12.3 Fleming Medical Ltd.
  • 12.4 Oystershell Consumer Health
  • 12.5 Parapro Pharmaceuticals
  • 12.6 Perrigo Company plc
  • 12.7 Prestige Consumer Healthcare Inc.
  • 12.8 Reckitt Benckiser Group plc
  • 12.9 Sanofi S.A.
  • 12.10 Thornton & Ross Ltd.